MedTrace Logo

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2015-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out whether atomoxetine (also called Strattera) helps teenagers (12-19) with Attention Deficit Hyperactivity Disorder (ADHD) and drug/alcohol problems.

Conditions

Interventions

DRUG

Atomoxetine

Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder

DRUG

Placebo

Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder

Sponsors & Collaborators

  • American Academy of Child Adolescent Psychiatry.

    collaborator OTHER

  • Denver Health and Hospital Authority

    lead OTHER

Principal Investigators

  • Christian C Thurstone, MD · Denver Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00399763 on ClinicalTrials.gov